{"nctId":"NCT01470144","briefTitle":"Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension","startDateStruct":{"date":"2011-06-01","type":"ACTUAL"},"conditions":["Pulmonary Arterial Hypertension"],"count":41,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Epoprostenol"]}],"interventions":[{"name":"Epoprostenol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed informed consent prior to initiation of any study-mandated procedure\n2. Patients who completed participation in study AC-066A301\n3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301\n\nExclusion Criteria:\n\n1. Patients who prematurely discontinued study drug in study AC-066A301\n2. Patients for whom continued treatment with EFI is no longer considered appropriate","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment-emergent Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Exposure Duration","description":"Duration of exposure to EFI","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":41},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Pain in extremity","Cough"]}}}